Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Gets NMPA Acceptance for FZ-P001 Phase II Lung Cancer Trial
I'm PortAI, I can summarize articles.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. received NMPA acceptance for its Phase II trial of FZ-P001 Sodium for Injection, aimed at visualizing malignant lesions in lung cancer patients. The company will advance the project and adhere to regulatory disclosure requirements. The news was published by Public Technologies using AI and is not financial advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments